The Discounted Cash Flow (DCF) valuation of Nektar Therapeutics (NKTR) is (47.40) USD. With the latest stock price at 1.01 USD, the upside of Nektar Therapeutics based on DCF is -4793.4%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.1% - 7.9% | 7.0% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (121.17) - (30.19) | (47.40) |
| Upside | -12097.0% - -3089.5% | -4793.4% |